The delayed effect of the neuroprotector fabomotizole on the brain proteome in rats with the rotenone model of parkinsonism

Fabomotizole is an original anxiolytic agent developed at the Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies that acts on a number of important receptor systems of the brain. In a model of Parkinson's disease induced in rats by a course of rotenone...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Biomeditsinskaia khimiia Ročník 71; číslo 3; s. 217
Hlavní autoři: Buneeva, O A, Kapitsa, I G, Zavyalova, M G, Kaloshina, S A, Zgoda, V G, Medvedev, A E
Médium: Journal Article
Jazyk:angličtina
Vydáno: Russia (Federation) 01.06.2025
Témata:
Animals
Benzimidazoles
Brain - drug effects
Brain - metabolism
Brain - pathology
Disease Models, Animal
Male
Morpholines
Nerve Tissue Proteins - metabolism
Neuroprotective Agents - pharmacology
Parkinson Disease, Secondary - chemically induced
Parkinson Disease, Secondary - drug therapy
Parkinson Disease, Secondary - metabolism
Parkinsonian Disorders - chemically induced
Parkinsonian Disorders - drug therapy
Parkinsonian Disorders - metabolism
Proteome - metabolism
Rats
Rats, Wistar
Rotenone - toxicity
neurodegeneration
rotenone
proteomic profiling
fabomotizole
brain proteins
neuroprotector
ISSN:2310-6972
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Fabomotizole is an original anxiolytic agent developed at the Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies that acts on a number of important receptor systems of the brain. In a model of Parkinson's disease induced in rats by a course of rotenone administration, fabomotizole attenuated manifestations of behavioral impairments and influenced the profile and relative content of brain proteins. Five days after the last administration of rotenone, the fabomotizole effect on the behavioral reactions of rats persisted. According to the proteomic study, the profile of brain proteins and changes in their relative content differed significantly from the results obtained immediately after the last administration of rotenone, as well as rotenone in combination with fabomotizole. Changes in the relative content of almost all proteins detected immediately after the last administration of rotenone or rotenone with fabomotizole were not detectable five days later. However, at this time point, there were changes in the relative content of other proteins associated with neurodegeneration in Parkinson's and Alzheimer's diseases. Such dynamics suggests a wave-like change in the content of pathogenetically important brain proteins involved in the mechanisms of neurodegeneration and neuroprotection.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2310-6972
DOI:10.18097/PBMCR1586